Nicotine in Combination with SARS-CoV-2 Affects Cells Viability, Inflammatory Response and Ultrastructural Integrity

Int J Mol Sci. 2022 Aug 22;23(16):9488. doi: 10.3390/ijms23169488.

Abstract

The aims of our study are to: (i) investigate the ability of nicotine to modulate the expression level of inflammatory cytokines in A549 cells infected with SARS-CoV-2; (ii) elucidate the ultrastructural features caused by the combination nicotine+SARS-CoV-2; and (iii) demonstrate the mechanism of action. In this study, A549 cells pretreated with nicotine were either exposed to LPS or poly(I:C), or infected with SARS-CoV-2. Treated and untreated cells were analyzed for cytokine production, cytotoxicity, and ultrastructural modifications. Vero E6 cells were used as a positive reference. Cells pretreated with nicotine showed a decrease of IL6 and TNFα in A549 cells induced by LPS or poly(I:C). In contrast, cells exposed to SARS-CoV-2 showed a high increase of IL6, IL8, IL10 and TNFα, high cytopathic effects that were dose- and time-dependent, and profound ultrastructural modifications. These modifications were characterized by membrane ruptures and fragmentation, the swelling of cytosol and mitochondria, the release of cytoplasmic content in extracellular spaces (including osmiophilic granules), the fragmentation of endoplasmic reticulum, and chromatin disorganization. Nicotine increased SARS-CoV-2 cytopathic effects, elevating the levels of inflammatory cytokines, and inducing severe cellular damage, with features resembling pyroptosis and necroptosis. The protective role of nicotine in COVID-19 is definitively ruled out.

Keywords: SARS-CoV-2; cytokines; human lung adenocarcinoma A549 cells; necroptosis; nicotine; poly(I:C); proinflammatory cytokines; pyroptosis.

MeSH terms

  • A549 Cells
  • COVID-19
  • Cell Survival / drug effects
  • Cytokines / metabolism
  • Humans
  • Interleukin-6
  • Lipopolysaccharides
  • Nicotine* / adverse effects
  • Nicotine* / pharmacology
  • SARS-CoV-2*
  • Tumor Necrosis Factor-alpha

Substances

  • Cytokines
  • Interleukin-6
  • Lipopolysaccharides
  • Tumor Necrosis Factor-alpha
  • Nicotine

Grants and funding

This research is supported by funds from the Italian Health Ministry (Ricerca Corrente to P.R., L.V., M.A.R.) 2021, Roma Italy, and Fondazione Roma (MEBIC #18/6/2019).